Late-Breaking & Featured Science – Scientific Sessions 2024

LBS.01 in Program Planner
Note: LBS.01 is part of the Opening General Session
Saturday, November 11, 2023, 8:30 a.m. – 9:15 a.m. ET
Main Event I

• SELECT – Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes

LBS.02 in Program Planner
Saturday, November 11, 2023, 9:45 a.m. – 11:00 a.m. ET
Main Event I

• DAPA-MI – A Registry-Based Randomized Trial of Dapagliflozin in Patient with Acute Myocardial Infarction Without Diabetes
• MINT – Restrictive versus Liberal Blood Transfusion in Patients with Myocardial Infarction and Anemia: Results of the MINT Trial
• ORBITA-2 – Percutaneous Coronary Intervention for Stable Angina: A Randomized, Placebo-Controlled Trial

LBS.03 in the Program Planner
Saturday, November 11, 2023, 1:30 p.m. – 2:45 p.m. ET
Main Event I

• ARIES HM3 – Avoidance of Aspirin with Left Ventricular Assist Devices in Advanced Heart Failure: Primary Results of the International, Double-Blind, Placebo-Controlled ARIES HM3 Trial
• The TEAMMATE Trial – Everolimus to Prevent Rejections in Children after Cardiac Transplantation
• Integrating Cost Into Shared Decision-Making for Heart Failure With Reduced Ejections Fraction: A Trial Providing Out-of-Pocket Costs for Heart Failure Medications During Clinical Encounters

LBS.04 in Program Planner
Saturday, November 11, 2022, 3:15 p.m. – 4:30 p.m. ET
Main Event I

• CRHCP – Effectiveness of Blood Pressure-Lowering Intervention of Risk of Total Dementia Among Patients with Hypertension: A Cluster-Randomized Effectiveness Trial
• POP-HT – Long-Term Blood Pressure Control After Physician Optimised Postpartum Blood Pressure Self-Management: The POP-HT Randomised Clinical Trial
• CARDIA-SSBP – Effects of Dietary Sodium on Systolic Blood Pressure in Middle-Aged Individuals: A Randomized Order Cross-Over Trial
• KARDIA-1 – Sustained Blood Pressure Reduction with the RNA Interference Therapeutic Zilebesiran: Primary Results from KARDIA-1, a Phase 2 Study in Patients With Hypertension

LBS.05 in Program Planner
Sunday, November 12, 2023, 8:00 a.m. – 9:15 a.m. ET
Main Event 1

• Efficacy and Safety of Dual Direct Current Cardioversion versus Single Direct Ccurrent Cardioversion as an Inital Treatment Strategy in Obese Patients with Atrial Fibrillation
• AZALEA-TIMI 71 – Abelacimab, a Novel Factor XI/XIa Inhibitor, vs Rivaroxaban in Patients with Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial
• NOAH-AFNET 6 – Efficacy and Safety of Anticoagulation with Edoxaban in Patients with AHRE Durations > 24 Hours: The NOAH-AFNET 6 Trial
• ARTESIA – Apixaban for the Prevention of Stroke in Patients with Subclinical Atrial Fibrillation

LBS.06 in Program Planner
Sunday, November 12, 2023, 3:30 p.m. – 4:45 p.m. ET
Main Event 1

• VERVE-101 – Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b heart-1 Trial
• Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein(a)
• REMAIN-2 – Recaticimab Add-on Therapy in Patients With Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
• REPRIEVE – Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarks in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV

LBS.07 in Program Planner
Monday, November 13, 2023, 8:00 a.m. – 9:15 a.m. ET
Main Event I

• ESPRIT – Effects of Intensive Blood Pressure Lowering Treatment in Reducing Risk of Cardiovascular Events
• IMPACTS – Effect of a Multifaceted Implementation Strategy on Blood Pressure Control in Low-Income Patients: A Cluster Randomized Trial
• A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients
• HTN Program – Hypertension Treatment in Nigeria Program: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

LBS.08 in Program Planner
Monday, November 13, 2023, 9:45 a.m. – 11:00 a.m.
Main Event I

• SPEC-AI – Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial
• Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients
• ARISE – Artificial Intelligence Enabled Rapid Identification of ST-Elevation Myocardial Infarction Using Electorcardiogram: A Pragmatic Randomized Controlled Trial
• ORFAN – Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging Study

FS.01 in Program Planner
Saturday, November 11, 2023, 9:45 a.m. - 11:00 a.m.

• MANIFEST-10K - Multi-National Survey on the Safety of the Post-Approval Clinical Use of Pulsed Field Ablation in 10,000+ Patients
  
  
• ReVeRA-201 Phase 2 - Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation
  
  
• I-CLAS - Arrhythmic Risk in Biventricular Pacing Compared to Left Bundle Branch Area Pacing: Results From International Collaborative LBBAP Study
   
• EMPA-ICD - Effect of Empagliflozin on Ventricular Arrhythmias in Patients with Type 2 Diabetes Treated with an Implantable Cardioverter-Defibrillator

FS.02 in Program Planner
Saturday, November 11, 2023, 1:30 p.m. - 2:45 p.m.

• Left Anterior Descending Non-culprit Lesion Location And Clinical Outcomes In Patients With St-segment Elevation Myocardial Infarction And Multivessel Disease: Results From The Complete Trial
   
• PRECISE - Resource Use and Cost Comparisons of a Novel Precision Medicine Evaluation Strategy for Suspected Coronary Artery Disease versus Usual Testing: Results From the PRECISE Randomized Trial
  
  
• ISCHEMIA post-hoc analysis - PCI or CABG versus Medical Therapy in the ISCHEMIA Trial: A Post Hoc Analysis
  
  
• ECLS-SHOCK - Impact of Cardiac Arrest Before Randomization on the Efficacy of ECLS in Patients With Infarct-Related Cardiogenic Shock. A Sub-Analysis of the Prospective EClS-Shock Trial
  
  

FS.03 in Program Planner
Sunday, November 12, 2023 8:00 a.m. - 9:15 a.m.

• Acute Hemodynamic Study of Oral TPN171H In Patients With Pulmonary Arterial Hypertension: A Multicenter, Randomized, Controlled, Phase 2 Clinical Trial
  
  
• Phase I Result of a Novel Antiplatelet Drug CG-0255 That is Fast-Acting, Long Lasting and Available for Either IV or Oral Administration
  
  
• Safety and Blood Pressure Lowering Effects of a Novel and Long-Acting Natriuretic Peptide Receptor 1 Agonist in Healthy Participants: A First-in-Human Clinical Study
  
  
• BioVAT-HF-DZHK20 - Safety And Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium As Biological Ventricular Assist Tissue In Terminal Heart Failure 
  
  
• Phase 1 Gene Therapy Trial in Patients With Advanced Heart Failure Using A Novel Cardiotropic AAV Vector Targeting Protein Phosphatase Inhibitor-1

FS.04 in Program Planner
Sunday, November 12, 2023 9:45 a.m. - 11:00 a.m.

• STEP-HFpEF Trial - Effects Of Semaglutide On Symptoms, Function And Quality Of Life In Patients With The Obesity Phenotype Of Heart Failure With Preserved Ejection Fraction: The Step-hfpef Trial
  
  
• Sodium-Glucose Cotransporter-2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
  
  
• ATTRibute-CM - Acoramidis Improves Clinical Outcomes In Transthyretin Amyloid Cardiomyopathy Patients

FS.05 in Program Planner
Monday, November 13, 8:00 a.m. to 9:15 a.m.

• STREAM-2 -  Half-dose Tenecteplase Or Primary PCI In Older Patients With St-elevation Myocardial Infarction: The STREAM-2 1-year Mortality Follow-up Results
   
• ARTICA - Pre-Hospital Rule-Out of Non-ST-Segment Elevation Acute Coronary Syndrome by a Single Troponin Measurement: Final One-Year Outcomes of the ARTICA Randomised Trial  
   
• FAST-MI - Association of Use and Dose of Lipid Lowering Therapy Post Acute Myocardial Infarction in the Elderly With 5-year Survival: The French Registry on ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry
  
  
• STEMI - Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction (STEMI)
  
  
• STEROHCA - Prehospital High-Dose Glucocorticoid Treatment for Post-Cardiac Arrest Syndrome Following Resuscitated Out-of-Hospital Cardiac Arrest: The STEROHCA Trial

FS.06 in Program Planner
Monday, November 13, 2023, 9:45 a.m. - 11:00 a.m.

• Incidence and Causes of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-year Study
  
  
• LIVE-LQTS - Vigorous Exercise in Individuals With Long QT Syndrome (LQTS): Primary Results of the Prospective, Multinational Lifestyle and Exercise in LQTS (LIVE-LQTS) Study
  
  
• Safety And Efficacy Of The Jewel, A Novel Patch Wearable Cardioverter Defibrillator: Results From The Jewel Investigational Device Exemption Study
   
• WATCHFUL - Effect of a Walking Intervention on Functional Capacity in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial
  
  
• LEAF - The Liraglutide Effect on Atrial Fibrillation (LEAF) Study

FS.07 in Program Planner
Monday, November 13, 2023 1:30 p.m. - 2:45 p.m.

• KABUKI - A Multicenter, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial
  
  
• SPECIAL - Ultrasound-assisted Catheter-directed Thrombolysis Versus Surgical Pulmonary Embolectomy For Intermediate-high Or High-risk Pulmonary Embolism: A Randomized Phase II Non-inferiority Study
   
• NICE - Nicotinamide Riboside to Improve Walking Performance in Peripheral Artery Disease: A Randomized Clinical Trial
  
  
• PROMINENT - Pemafibrate Reduces Incidence of Lower Extremity Ischemic Ulcer and Gangrene: Evidence From PROMINENT